Viruses, Vol. 13, Pages 1768: Nafamostat –Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2

Viruses, Vol. 13, Pages 1768: Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2 Viruses doi: 10.3390/v13091768 Authors: Aleksandr Ianevski Rouan Yao Hilde Lysvand Gunnveig Grødeland Nicolas Legrand Valentyn Oksenych Eva Zusinaite Tanel Tenson Magnar Bjørås Denis E. Kainov SARS-CoV-2 and its vaccine/immune-escaping variants continue to pose a serious threat to public health due to a paucity of effective, rapidly deployable, and widely available treatments. Here, we address these challenges by combining Pegasys (IFNα) and nafamostat to effectively suppress SARS-CoV-2 infection in cell culture and hamsters. Our results indicate that Serpin E1 is an important mediator of the antiviral activity of IFNα and that both Serpin E1 and nafamostat can target the same cellular factor TMPRSS2, which plays a critical role in viral replication. The low doses of the drugs in combination may have several clinical advantages, including fewer adverse events and improved patient outcome. Thus, our study may provide a proactive solution for the ongoing pandemic and potential future coronavirus outbreaks, which is still urgently required in many parts of the world.
Source: Viruses - Category: Virology Authors: Tags: Brief Report Source Type: research

Related Links:

Eur Rev Med Pharmacol Sci. 2021 Oct;25(19):5947-5964. doi: 10.26355/eurrev_202110_26872.ABSTRACTThe recent Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) outbreak has resulted in coronavirus disease 2019 (COVID-19) pandemic worldwide, affecting millions of lives. Although vaccines are presently made available, and vaccination drive is in progress to immunize a larger population; still the risk of SARS-CoV-2 infection and related mortality is persistent amid threats of the third wave of the ongoing pandemic. In the scenario of unavailability of robust and efficient treatment modalities, it becomes essential to...
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Source Type: research
CONCLUSIONS: From the 3-month interim analysis, the vaccine exhibited a 65.30% efficacy at preventing COVID-19 illness with favorable safety and immunogenicity profiles.PMID:34620531 | DOI:10.1016/j.vaccine.2021.09.052
Source: Vaccine - Category: Allergy & Immunology Authors: Source Type: research
AbstractOn 11 March 2020, the World Health Organization declared the coronavirus disease 19 (COVID-19) outbreak a pandemic. In this context, several studies and clinical trials have been conducted since then, and many are currently ongoing, leading to the development of several COVID-19 vaccines with different mechanisms of action. People affected by multiple sclerosis (MS) have been considered high-risk subjects in most countries and prioritized for COVID-19 vaccination. However, the management of MS during the COVID-19 pandemic has represented a new challenge for MS specialists, particularly because of the initial lack o...
Source: Neurology and Therapy - Category: Neurology Source Type: research
This article has highlighted information about current vaccines approved for emergency use as well as those in various stages of clinical trials. Vaccine availability around the world is a promising development in the fight against the SARS-CoV-2 virus. We conducted a narrative review to present the current state and research on this situation, specific diagnosis, clinical manifestation, emergency approaches, herbal-based remedies, and COVID vaccines.PMID:34599450 | DOI:10.1007/s11356-021-16654-9
Source: Environmental Science and Pollution Research International - Category: Environmental Health Authors: Source Type: research
As the coronavirus disease 2019 (COVID-19) pandemic is ongoing and new variants of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are emerging, there is an urgent need for COVID-19 vaccines to control disease outbreaks by herd immunity. Surveillance of rare safety issues related to these vaccines is progressing, since more granular data emerge with regard to adverse events of COVID-19 vaccines during post-marketing surveillance. Interestingly, four cases of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) presenting with pauci-immune crescentic glomerulonephritis (GN) after COVID-1...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
One Monday in late February 2020, Lauren Gardner was working frantically. The website she’d been managing around the clock for the last month—which tracked cases of an emerging respiratory disease called COVID-19, and presented the spread in maps and charts—was, all of a sudden, getting inundated with visitors and kept crashing. As Gardner, an associate professor of engineering at Johns Hopkins University (JHU), struggled to get the site online again, an official in the Trump Administration falsely claimed on Twitter that JHU had deliberately censored the information. “Seems like bad timing to sto...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
samonti An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) started in December 2019 in China and then become pandemic in February 2020. Several publications investigated the possible increased rate of COVID-19 infection in hematological malignancies. Based on the published data, strategies for the management of chronic Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) are provided. The risk of severe COVID-19 seems high in MPN, particularly in patients with essential thrombocythemia, but not negligible in myelofibrosis. MPN patients are at high risk of both thrombotic and hemorrh...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
The rapid outbreak of COVID-19 caused by the novel coronavirus SARS-CoV-2 in Wuhan, China, has become a worldwide pandemic affecting almost 204 million people and causing more than 4.3 million deaths as of August 11 2021. This pandemic has placed a substantial burden on the global healthcare system and the global economy. Availability of novel prophylactic and therapeutic approaches are crucially needed to prevent development of severe disease leading to major complications both acutely and chronically. The success in fighting this virus results from three main achievements: (a) Direct killing of the SARS-CoV-2 virus; (b) ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
This article reviews what is known about the humoral and cellular immune responses to SARS-CoV-2 and how mutation and structural/functional changes in the emerging variants of concern impact upon the immune protection from prior infection or vaccination.
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research
Tahmina Shirin Diverse coronavirus (CoV) strains can infect both humans and animals and produce various diseases. CoVs have caused three epidemics and pandemics in the last two decades, and caused a severe impact on public health and the global economy. Therefore, it is of utmost importance to understand the emergence and evolution of endemic and emerging CoV diversity in humans and animals. For diverse bird species, the Infectious Bronchitis Virus is a significant one, whereas feline enteric and canine coronavirus, recombined to produce feline infectious peritonitis virus, infects wild cats. Bovine and canine CoVs ha...
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research
More News: Coronavirus | COVID-19 | International Medicine & Public Health | Outbreaks | Pandemics | Pegasys | SARS | Study | Vaccines | Virology